Temprian Therapeutics is developing an MBEH-nanoparticle-based drug that delivers a toxic active ingredient directly to metastatic melanoma cells while enhancing the immune response. This targeted approach aims to improve treatment outcomes for patients with advanced melanoma by complementing existing therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Metastatic melanoma, an aggressive form of skin cancer, presents significant treatment challenges due to its ability to spread and resist conventional therapies. Current melanoma treatments often lack specificity, leading to systemic toxicity and limited efficacy in targeting metastatic cells.
Solution
Temprian Therapeutics is developing a targeted drug delivery system based on MBEH-nanoparticle technology designed to selectively target and destroy metastatic melanoma cells. The MBEH-nanoparticles encapsulate a toxic active ingredient and deliver it directly to the tumor site, minimizing exposure to healthy tissues. This approach aims to enhance the therapeutic effect while reducing the adverse side effects associated with traditional chemotherapy. By specifically targeting metastatic cells, the therapy seeks to improve treatment outcomes and overall survival rates for patients with advanced melanoma.
Target Audience
The primary target audience includes patients diagnosed with advanced or metastatic melanoma who require more effective and less toxic treatment options.
Features
- MBEH-nanoparticle drug delivery system for targeted delivery of therapeutics to metastatic melanoma cells.
- Encapsulation of a toxic active ingredient within the nanoparticles to maximize efficacy.
- Selective targeting of melanoma cells to minimize off-target effects and systemic toxicity.